1 Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track COVID-19 in real time. The Lancet Infectious Diseases 20, 533-534, doi:10.1016/S1473-3099(20)30120-1 (2020).
2 Wang, H.-y. et al. The psychological distress and coping styles in the early stages of the 2019 coronavirus disease (COVID-19) epidemic in the general mainland Chinese population: a web-based survey. PLoS One 15, e0233410, doi:10.1101/2020.03.27.20045807 (2020).
3 McKibbin, W. J. & Fernando, R. The global macroeconomic impacts of COVID-19: Seven scenarios. Centre for Applied Macroeconomica Analysis Working Paper No 19/2020, doi:https://dx.doi.org/10.2139/ssrn.3547729 (2020).
4 Sanders, J. M., Monogue, M. L., Jodlowski, T. Z. & Cutrell, J. B. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA 323, 1824-1836 (2020).
5 Dhama, K. et al. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Human Vaccines & Immunotherapeutics, 1-7 (2020).
6 Oettinger, T., Jørgensen, M., Ladefoged, A., Hasløv, K. & Andersen, P. Development of the Mycobacterium bovis BCG vaccine: review of the historical and biochemical evidence for a genealogical tree. Tubercle and lung disease 79, 243-250 (1999).
7 Roy, A. et al. Effect of BCG vaccination against Mycobacterium tuberculosisinfection in children: systematic review and meta-analysis. BMJ : British Medical Journal 349, g4643, doi:10.1136/bmj.g4643 (2014).
8 Aaby, P. et al. Randomized trial of BCG vaccination at birth to low-birth-weght cildren: Beneficial nnspecific efects in the nonatal priod? The Journal of Infectious Diseases 204, 245-252, doi:10.1093/infdis/jir240 (2011).
9 Sylvester, R. J., van der MEIJDEN, A. P. & Lamm, D. L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. The Journal of urology 168, 1964-1970 (2002).
10 Arts, R. J. et al. BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity. Cell host & microbe 23, 89-100. e105 (2018).
11 Leentjens, J. et al. BCG vaccination enhances the immunogenicity of subsequent influenza vaccination in healthy volunteers: a randomized, placebo-controlled pilot study. The Journal of infectious diseases 212, 1930-1938 (2015).
12 Kleinnijenhuis, J. et al. Long-lasting effects of BCG vaccination on both heterologous Th1/Th17 responses and innate trained immunity. J Innate Immun 6, 152-158, doi:10.1159/000355628 (2014).
13 Hegarty, P. K., Sfakianos, J. P., Giannarini, G., DiNardo, A. R. & Kamat, A. M. COVID-19 and bacillus Calmette-Guérin: What is the link? European Urology Oncology, S2588-9311(2520)30049-30043 (2020).
14 Miller, A. et al. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study. MedRxiv (2020).
15 Sala, G. & Miyakawa, T. Association of BCG vaccination policy with prevalence and mortality of COVID-19. medRxiv (2020).
16 Bruin, J. UCLA: Statistical Consulting Group., <https://stats.idre.ucla.edu/stata/ado/analysis/> (2006).
17 Hale, T., Petherick, A., Phillips, T. & Webster, S. Variation in government responses to COVID-19. Blavatnik School of Government Working Paper 31 (2020).
18 Charrad, M., Ghazzali, N., Boiteau, V. & Niknafs, A. Determining the number of clusters using NbClust package. MSDM 2014, 1 (2014).
19 Nguipdop-Djomo, P., Heldal, E., Rodrigues, L. C., Abubakar, I. & Mangtani, P. Duration of BCG protection against tuberculosis and change in effectiveness with time since vaccination in Norway: a retrospective population-based cohort study. The Lancet infectious diseases 16, 219-226 (2016).
20 Lord, J. et al. Economic modelling of diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project. Health technology assessment (Winchester, England) 17, 1-192 (2013).
21 WHO-UNICEF. WHO vaccine-preventable diseases: monitoring system 2019 global summary. Geneva (CH): World Health Organization; 2019 https://apps.who.int/immunization_monitoring/globalsummary/timeseries/tswucoveragedtp3.html> (2019).
22 Dowd, J. B. et al. Demographic science aids in understanding the spread and fatality rates of COVID-19. Proceedings of the National Academy of Sciences 117, 9696-9698 (2020).
23 Redelman-Sidi, G. Could BCG be used to protect against COVID-19? Nature Reviews Urology, 1-2 (2020).
24 Shet, A., Ray, D., Malavige, N., Santosham, M. & Bar-Zeev, N. Differential COVID-19-attributable mortality and BCG vaccine use in countries. medRxiv (2020).
25 Bhatraju, P. K. et al. Covid-19 in Critically Ill Patients in the Seattle Region — Case Series. New England Journal of Medicine 382, 2012-2022, doi:10.1056/NEJMoa2004500 (2020).
26 Kraemer, M. U. G. et al. The effect of human mobility and control measures on the COVID-19 epidemic in China. Science 368, 493-497, doi:10.1126/science.abb4218 (2020).
27 Cohen, J. & Kupferschmidt, K. 1287-1288 (American Association for the Advancement of Science, 2020).
28 Hensel, J. et al. Exercising caution in correlating COVID-19 incidence and mortality rates with BCG vaccination policies due to variable rates of SARS CoV-2 testing. medRxiv (2020).
29 Hamiel, U., Kozer, E. & Youngster, I. SARS-CoV-2 Rates in BCG-Vaccinated and Unvaccinated Young Adults. JAMA, doi:10.1001/jama.2020.8189 (2020).
30 Song, J.-Y., Yun, J.-G., Noh, J.-Y., Cheong, H.-J. & Kim, W.-J. Covid-19 in South Korea—challenges of subclinical manifestations. New England Journal of Medicine 382, 1858-1859 (2020).
31 Mills, G., Cullen, W., Moore, N. & Foley, R. Making sense of publicly available data on COVID-19 in Ireland. medRxiv (2020).